Description: VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
Home Page: vectivbio.com
VECT Technical Analysis
Aeschenvorstadt 36
Basel,
4051
Switzerland
Phone:
41 61 551 30 3
Officers
| Name | Title |
|---|---|
| Dr. Luca Santarelli M.D. | Founder, CEO & Director |
| Ms. Claudia D'Augusta Ph.D. | Chief Financial Officer |
| Dr. Christian Meyer M.D., Ph.D. | Chief Operating Officer |
| Dr. Alain Bernard Ph.D. | Chief Technology Officer |
| Mr. Patrick Malloy | Sr. VP of Investor Relations & Strategic Communications |
| Mr. Scott Applebaum | Chief Legal Officer & Corp. Sec. |
| Mr. Michael Steininger | Sr. VP & Head of HR |
| Mr. Kevin Harris M.B.A. | Chief Commercial Officer |
| Dr. Sarah Holland Ph.D. | Chief Bus. Officer |
| Dr. Omar Khwaja M.D., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.6229 |
| Price-to-Sales TTM: | 21.079 |
| IPO Date: | 2021-04-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |